Clinical Trial Search

Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73

Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031

Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…

Primary: Number of Participants With Prostate Cancer — 473; 432; 437; 416 participants — p=< .01

Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190

Primary: Change of Total Urine SFN (Sulforaphane) Metabolites — 4.75; -0.02 micromolar (µM) concentrations of urina

Primary: Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach) — 578; 435; 280; 224 participants — p=<0.0001

Primary: Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer — 0.86 ng/mL — p==0.027

Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants

Primary: Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months — -0.75; 1.55; 10.21; 4.89 Relative % difference

Primary: Pathology Status — 2.37; 1.73 number of positive cores

Primary: Percentage of Patients Who Were Ready to Make a Decision or Were Undecided — 134; 90; 144; 125 Participants

Primary: Fatty Acid Synthase Expression by Immunohistochemistry at Pre- and Post-intervention (FAS Summary Score) — 147; 158.8; 138.3; 102.3 units on a scale — p=0.1521

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio

Primary: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium in the Radical Prostatectomy Specimen Obtained After 8-weeks of the Dietary Intervention — 6.9; 5.0…

Primary: Median Change in Percent Ki-67 From Baseline — 0.5; 1.0; 1.0; 1.0 percentage of tumor cells

Primary: PSA Slope (Trajectory) or the Change in PSA Level Over Time — 0.59; 0.27 ng/mL

Primary: Feasibility - Recruitment — 39 Participants

Primary: Changes in Fatigue — 52.4; 53.4 T-score — p=0.454

Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants

Primary: Tissue Biomarkers

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Number of Participants With Biochemical Failure — 12; 52 Participants

Primary: Change in Prostate Cancer Knowledge as Measured by the Decisional Conflict Scale — 80; 70 score on a scale

Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2

Primary: Gene Expression of Phase II Enzymes — -0.36; 0.26; 0.15; -0.59 -fold change in expression

Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…

Primary: Impact of Weight Loss Before and Weight Maintenance After Prostate Cancer (PCa) Surgery on Immunosuppressive Factors — 19.29; 17.37; 17.68; 12.76 count of cells — p=0.6489

Primary: Number of Participants Who Had Prostate Specific Antigen (PSA) Discussion With Physician at 3 Months, Measured by Survey — 34; 30; 25; 22 participants — p=0.29